A-804598

A-804598
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

A-804598 is a potent and selective antagonist of the P2X7 receptor, a type of purinergic receptor that is activated by adenosine triphosphate (ATP). The P2X7 receptor is a ligand-gated ion channel that plays a significant role in the immune system, particularly in the process of inflammation and cell death.

Mechanism of Action

A-804598 functions by inhibiting the P2X7 receptor, which is known to mediate the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α). By blocking this receptor, A-804598 can reduce inflammation and has potential therapeutic applications in diseases characterized by excessive inflammatory responses.

Pharmacological Properties

A-804598 is characterized by its high selectivity for the P2X7 receptor over other P2X receptor subtypes. This selectivity is crucial for minimizing off-target effects and enhancing the therapeutic potential of the compound. The pharmacokinetics of A-804598, including its absorption, distribution, metabolism, and excretion, are subjects of ongoing research.

Therapeutic Potential

The inhibition of the P2X7 receptor by A-804598 has been explored in various preclinical models of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and neurodegenerative disorders such as Alzheimer's disease. The compound's ability to modulate immune responses makes it a promising candidate for the development of new anti-inflammatory therapies.

Research and Development

A-804598 is primarily used in research settings to study the role of the P2X7 receptor in health and disease. Its development as a therapeutic agent is still in the experimental stages, with ongoing studies aimed at understanding its efficacy and safety profile in various disease models.

Safety and Toxicology

As with any investigational compound, the safety and toxicological profile of A-804598 is critical. Preclinical studies are necessary to evaluate potential adverse effects and to establish safe dosage ranges for future clinical trials.

Also see

• P2X7 receptor
• Purinergic signaling
• Inflammation
• Cytokines
• Neurodegenerative diseases

Receptor Antagonists
Receptor Type	Example Antagonists
Adrenergic receptor	Propranolol, Prazosin
Cholinergic receptor	Atropine, Scopolamine
Dopamine receptor	Haloperidol, Clozapine
Histamine receptor	Ranitidine, Diphenhydramine
Serotonin receptor	Ondansetron, Risperidone
Glutamate receptor	Memantine, Ketamine
GABA receptor	Flumazenil, Bicuculline
Opioid receptor	Naloxone, Naltrexone
Angiotensin receptor	Losartan, Valsartan